Financial Highlights
Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016.
| Third Quarter (2021-07-01 – 2021-09-30) |
| Net revenues were TDKK 0 (0) |
| EBIT was TDKK -9,056 (-3,068) |
| Earnings per share was DKK –0.21 (-0.12) |
| Earnings per share, fully diluted was DKK –0.20 (-0.10) |
| First Nine Months of the Year (2021-01-01 – 2021-09-30) |
| Net revenues were TDKK 0 (0) |
| EBIT was TDKK -15,792 (-8,462) |
| Earnings per share was DKK –0.64 (-0.33) |
| Earnings per share, fully diluted was DKK –0.54 (-0.28) |
| Cash and bank: TDKK 41,394 (8,174) |
| Solidity: 72% (92%) |
Solidity: equity divided by assets.
Business highlights in Q3 2021
- On July 2nd it was announced that the board had decided to execute on the previously communicated preferential rights issue
- On July 8th the prospectus for the preferential rights issue was published
- On July 12th the subscription period of the preferential rights issue began
- On July 29th it was announced that the rights issue was oversubscribed for a total of 227 percent
- On August 13th the final day of trading in BTA in connection with the rights issue was announced
- On September 17th a screening agreement with US National Institute on Drug Abuse to evaluate anti-addictive properties of the company´s preclinical assets was announced
- On September 24th it was announced that the first patient in the IPED2015 Phase 2b trial was included
Business highlights after this reporting period
- On October 1st the result of the incentive program in the company was announced
- On October 8th it was announced that the company had received conditional approval for listing of the companys shares at Nasdaq First North Growth Market in Stockholm
- On October 18th the Information Memorandum in connection with the change of listing to Nasdaq First North Growth Market was published
- On October 18th it was announced that the CTA for a Phase 1 proof of principle study in neuropathic pain had been submitted
- On October 22nd it was announced that the company had been approved for listing at Nasdaq First North Growth Market
- On October 25th it was announced that the trading of the company’s shares started on October 25th